Formosa Pharmaceuticals announces development collaboration agreement with Eyenovia
February 15th 2023According to the companies, the collaboration will combine Formosa's APNT nanoparticle formulation platform with Eyenovia's Optejet dispensing technology for the development of new ophthalmic therapies in indications with significant unmet medical needs.
Being an ophthalmologist on an airplane: Tips in the event of a medical emergency during a flight
February 15th 2023Andrew G. Lee, MD, has had direct experience as being an in-flight physician over 15 times on international and domestic flights and answers some of the most frequently asked questions about being the doctor on the plane.
FDA accepts NDA, sets PDUFA date for Ocuphire Pharma’s mydriasis treatment
February 13th 2023If approved later this year, phentolamine ophthalmic solution 0.75% could be the only commercially available eye drop for the reversal of dilation. It is being developed for reversal of pharmacologically-induced mydriasis, presbyopia, and dim light vision disturbances under the 505(b)(2) pathway.
EnVision Summit 2023: Unique program takes family friendly conference to new heights
February 13th 2023Bonnie An Henderson, MD, founder and program director of EnVision Summit, previews what attendees can expect at this year’s meeting - from its diverse faculty to an inclusive Youth Program, while also giving back to the community. The conference will take place February 17 to 20 at the El Conquistador Resort in Fajardo, Puerto Rico.
Ellipsoid zone integrity in dry AMD focus of presentation at Angiogenesis 2023
February 10th 2023In a presentation at the Angiogenesis, Exudation, and Degeneration 2023 conference, Justis Ehlers, MD, presented "Ellipsoid Zone Integrity in Dry AMD: An Imaging Biomarker for Progression Risk and Clinical Trial Endpoint.”
Angiogenesis 2023: Visual functional loss in geographic atrophy
February 10th 2023In a presentation at the 2023 Angiogenesis, Exudation, and Degeneration program, Usha Chakravarthy, PhD, FRCOphth, CBE, presented data from the trial of lampalizumab, which is peeling back some of the mystery shrouding geographic atrophy.
Angiogenesis 2023: Ophthalmic artery angioplasty to treat age-related macular degeneration
February 10th 2023In a presentation at Bascom Palmer’s 2023 Angiogenesis, Exudation, and Degeneration conference in Miami, Pedro Lylyk, MD, said ophthalmic artery angioplasty could prove to be a treatment option for patients diagnosed with age-related macular degeneration.